We have known for over 60 years that prostate tissue is androgen regulated. Androgen deprivation (also referred to as suppression) therapy (ADT) remains the primary treatment for advanced stage prostate cancer. Despite these advances, there is clinical concern regarding an induced bone loss, often referred to as 'cancer treatment induced bone loss' (CTIBL). Men with prostate cancer who are initiating ADT have a 5-10 fold increased loss of bone density at multiple skeletal sites compared with either healthy controls or men with prostate cancer who are not on ADT, placing them at increased risk of fracture; bone loss was maximal in the first year after initiation of ADT, suggesting a window for the initiation of early preventive therapy. A significant clinical consequence of ADT-induced osteoporosis is bone fracture.